For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...

Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and safety ...

A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the ...

With a high recurrence rate following surgery to treat chronic sinusitis with nasal polyps, authors set out to investigate the effectiveness and safety of endoscopic sinus surgery (ESS) in a pediatric ...

Tezepelumab (Tezspire) has shown significant clinical benefits in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), including marked reductions in nasal congestion and polyp size ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...

x ray of sinusitis and nasal polyps Treatment with mepolizumab is associated with improvements in asthma exacerbation rates and health-related quality of life in patients with severe eosinophilic ...